Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Period	Debt/Equity
2017-12-31	0.10
2018-12-31	0.11
2019-12-31	0.42
2020-12-31	0.16
2021-12-31	0.94
2022-12-31	0.64
2023-12-31	0.71
2024-12-31	1.40

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRO	$2.43	+0.00%	0.21M
3
4
5

Spero Therapeutics Inc. (SPRO) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Spero Therapeutics Inc. Data in Excel

More SPRO Financial Data